| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BRKR Stock Overview
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally.
Rewards
PE ratio (39.7x) is below the Life Sciences industry average (39.9x)
Risk Analysis
No risks detected for BRKR from our risk checks.
Bruker Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$70.72 |
| 52 Week High | US$92.35 |
| 52 Week Low | US$54.46 |
| Beta | 1.23 |
| 1 Month Change | -9.97% |
| 3 Month Change | -8.76% |
| 1 Year Change | 19.78% |
| 3 Year Change | 104.87% |
| 5 Year Change | 216.99% |
| Change since IPO | 206.65% |
Recent News & Updates
What Is Bruker Corporation's (NASDAQ:BRKR) Share Price Doing?
Today we're going to take a look at the well-established Bruker Corporation ( NASDAQ:BRKR ). The company's stock...
Here's Why I Think Bruker (NASDAQ:BRKR) Is An Interesting Stock
It's only natural that many investors, especially those who are new to the game, prefer to buy shares in 'sexy' stocks...
Shareholder Returns
| BRKR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -4.6% | -1.8% | -0.5% |
| 1Y | 19.8% | 9.6% | 13.7% |
Return vs Industry: BRKR exceeded the US Life Sciences industry which returned 9.6% over the past year.
Return vs Market: BRKR exceeded the US Market which returned 13.7% over the past year.
Price Volatility
| BRKR volatility | |
|---|---|
| BRKR Average Weekly Movement | 4.5% |
| Life Sciences Industry Average Movement | 8.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: BRKR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: BRKR's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 7,400 | Frank Laukien | https://www.bruker.com |
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies; and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection.
Bruker Fundamentals Summary
| BRKR fundamental statistics | |
|---|---|
| Market Cap | US$10.73b |
| Earnings (TTM) | US$270.30m |
| Revenue (TTM) | US$2.36b |
39.7x
P/E Ratio4.5x
P/S RatioIs BRKR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BRKR income statement (TTM) | |
|---|---|
| Revenue | US$2.36b |
| Cost of Revenue | US$1.18b |
| Gross Profit | US$1.19b |
| Expenses | US$915.10m |
| Earnings | US$270.30m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.78 |
| Gross Margin | 50.19% |
| Net Profit Margin | 11.44% |
| Debt/Equity Ratio | 78.0% |
How did BRKR perform over the long term?
See historical performance and comparisonDividends
0.2%
Current Dividend Yield9%
Payout RatioValuation
Is Bruker undervalued compared to its fair value and its price relative to the market?
39.68x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BRKR ($70.72) is trading above our estimate of fair value ($61.96)
Significantly Below Fair Value: BRKR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BRKR is good value based on its PE Ratio (39.7x) compared to the US Life Sciences industry average (39.9x).
PE vs Market: BRKR is poor value based on its PE Ratio (39.7x) compared to the US market (17.4x).
Price to Earnings Growth Ratio
PEG Ratio: BRKR is poor value based on its PEG Ratio (3.8x)
Price to Book Ratio
PB vs Industry: BRKR is overvalued based on its PB Ratio (10x) compared to the US Life Sciences industry average (3.3x).
Future Growth
How is Bruker forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
10.6%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BRKR's forecast earnings growth (10.6% per year) is above the savings rate (2%).
Earnings vs Market: BRKR's earnings (10.6% per year) are forecast to grow slower than the US market (13% per year).
High Growth Earnings: BRKR's earnings are forecast to grow, but not significantly.
Revenue vs Market: BRKR's revenue (5.7% per year) is forecast to grow slower than the US market (9.3% per year).
High Growth Revenue: BRKR's revenue (5.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BRKR's Return on Equity is forecast to be high in 3 years time (26.8%)
Past Performance
How has Bruker performed over the past 5 years?
12.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BRKR has high quality earnings.
Growing Profit Margin: BRKR's current net profit margins (11.4%) are higher than last year (8%).
Past Earnings Growth Analysis
Earnings Trend: BRKR's earnings have grown by 12% per year over the past 5 years.
Accelerating Growth: BRKR's earnings growth over the past year (71.6%) exceeds its 5-year average (12% per year).
Earnings vs Industry: BRKR earnings growth over the past year (71.6%) underperformed the Life Sciences industry 72.2%.
Return on Equity
High ROE: BRKR's Return on Equity (25.3%) is considered high.
Financial Health
How is Bruker's financial position?
Financial Position Analysis
Short Term Liabilities: BRKR's short term assets ($2.0B) exceed its short term liabilities ($921.2M).
Long Term Liabilities: BRKR's short term assets ($2.0B) exceed its long term liabilities ($1.1B).
Debt to Equity History and Analysis
Debt Level: BRKR's net debt to equity ratio (15.9%) is considered satisfactory.
Reducing Debt: BRKR's debt to equity ratio has increased from 52.1% to 78% over the past 5 years.
Debt Coverage: BRKR's debt is well covered by operating cash flow (40.8%).
Interest Coverage: BRKR earns more interest than it pays, so coverage of interest payments is not a concern.
Balance Sheet
Dividend
What is Bruker current dividend yield, its reliability and sustainability?
0.23%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BRKR's dividend (0.23%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.32%).
High Dividend: BRKR's dividend (0.23%) is low compared to the top 25% of dividend payers in the US market (3.44%).
Stability and Growth of Payments
Stable Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: BRKR is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: BRKR is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BRKR's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
11.8yrs
Average management tenure
CEO
Frank Laukien (61 yo)
30.92yrs
Tenure
US$4,081,963
Compensation
Dr. Frank H. Laukien, Ph D., serves as the Chairman, Chief Executive Officer and President of Bruker Corporation at Bruker BioSpin GmbH since February 1991. Dr. Laukien serves as the Chairman, Chief Execut...
CEO Compensation Analysis
Compensation vs Market: Frank's total compensation ($USD4.08M) is below average for companies of similar size in the US market ($USD11.18M).
Compensation vs Earnings: Frank's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: BRKR's management team is seasoned and experienced (11.8 years average tenure).
Board Members
Experienced Board: BRKR's board of directors are considered experienced (6.4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Bruker Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Bruker Corporation
- Ticker: BRKR
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$10.725b
- Shares outstanding: 151.66m
- Website: https://www.bruker.com
Number of Employees
Location
- Bruker Corporation
- 40 Manning Road
- Billerica
- Massachusetts
- 1821
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/16 23:05 |
| End of Day Share Price | 2022/01/14 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.